☆ 4.3 Editorial Material

Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?

EXPERT OPINION ON BIOLOGICAL THERAPY (2019)

Journal

EXPERT OPINION ON BIOLOGICAL THERAPY

Volume 19, Issue 11, Pages 1107-1110

Publisher

TAYLOR & FRANCIS LTD

DOI: 10.1080/14712598.2019.1651288

Keywords

Biomarker; immunotherapy; tumor mutational burden; renal cell carcinoma; PD-L1; metastases

Categories

Biotechnology & Applied Microbiology Medicine, Research & Experimental

Funding

Pfizer
Merck
BMS
Roche

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Immunology

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades

Xuan Zhao, Yulin Bao, Bi Meng, Zijian Xu, Sijin Li, Xu Wang, Rui Hou, Wen Ma, Dan Liu, Junnian Zheng, Ming Shi

Summary: Developing biomarkers for predicting the efficacy of immune checkpoint inhibitor therapies is important for avoiding side effects and economic burden. Current assays evaluating PD-L1 expression are imperfect, but recent studies are advancing the methodologies to improve accuracy. This includes standardization of immunohistochemistry tests and the use of novel in vivo probes and liquid biopsy. Considering PD-L1 expression on non-tumor cells and utilizing artificial intelligence can further enhance the predictive accuracy of PD-L1 as a biomarker.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Cell Biology

A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma

Congkuan Song, Zhiquan Wu, Qingwen Wang, Yujin Wang, Zixin Guo, Sheng Li, Weidong Hu

Summary: A study identified two genes that can predict response to immunotherapy in lung adenocarcinoma patients, developed a signature to distinguish high- and low-risk patients, and constructed a nomogram by combining immune prognostic signature with clinical features.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Article Oncology

Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases

A. Steindl, D. Alpar, G. Heller, M. J. Mair, B. Gatterbauer, K. Dieckmann, G. Widhalm, J. A. Hainfellner, M. Schmidinger, C. Bock, L. Muellauer, M. Preusser, A. S. Berghoff

Summary: The study found that there was no significant difference in tumor mutational burden (TMB) and density of tumor-infiltrating lymphocytes (TIL) between primary/extracranial renal cell carcinoma (RCC) specimens and matched brain metastases (BM). Higher densities of CD8+ TIL and CD45RO+ TIL were observed in primary tumors compared to intracranial samples collected after systemic treatment.

ESMO OPEN (2021)

Add to Collection

Review Immunology

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

Qian Li, Jingjing Han, Yonglin Yang, Yu Chen

Summary: Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. In recent years, immunotherapy using immune checkpoint inhibitors, particularly targeting the PD-1/PD-L1 axis, has brought fundamental changes to the treatment of advanced HCC. However, challenges remain and combination therapy may be a better option to improve the low remission rate.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression

Richard S. P. Huang, Brennan Decker, Karthikeyan Murugesan, Matthew Hiemenz, Douglas A. Mata, Gerald Li, James Creeden, Shakti H. Ramkissoon, Jeffrey S. Ross

Summary: The study found low prevalence of non-amplification short variants (SV) mutations in CD274, with mutation types and rates varying by tumor type. Specific mutation types may affect the expression level of PD-L1 protein and potentially function as resistance biomarkers in ICPI therapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Medicine, Research & Experimental

Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-L1 expression

Meng Gao, Dongjian Zhang, Cuihua Jiang, Qiaomei Jin, Jian Zhang

Summary: Paeoniflorin inhibits PD-L1 expression on hepatocellular carcinoma (HCC) cells and exhibits anti-tumor effects by promoting T cell-mediated immune responses. Paeoniflorin also suppresses PD-L1 expression through the SOCS3/STAT3 signaling pathway. These findings provide novel insights into the anticancer effects of paeoniflorin.

BIOMEDICINE & PHARMACOTHERAPY (2023)

Add to Collection

Article Oncology

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer

Libin Zhang, Yanhui Chen, Han Wang, Zheyuan Xu, Yang Wang, Sixing Li, Jun Liu, Yun Chen, Hongli Luo, Lijia Wu, Ying Yang, Henghui Zhang, Hao Peng

Summary: CD8+PD-L1+ tumor-infiltrating lymphocytes in the tumor microenvironment of non-small cell lung cancer can serve as an indicator of a hot but immunosuppressive environment related to high tumor mutation burden. In immunotherapy, blocking the PD-1 pathway can help alleviate immunosuppression and lead to better treatment outcomes.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis

Jaeyun Jung, You Jeong Heo, Sehhoon Park

Summary: TMB status was analyzed using the TSO500 assay, and TMB-H was observed in 14.7% of the pan-cancer population. The study found that TMB-H patients had a higher response rate to anti-PD-(L)1 therapy, especially in gastric cancer, cholangiocarcinoma, melanoma, etc. Furthermore, patients with TMB >= 16 mut/Mb had prolonged survival after anti-PD-(L)1 therapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

Article Oncology

Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression

Richard S. P. Huang, Karthikeyan Murugesan, Meagan Montesion, Dean C. Pavlick, Douglas A. Mata, Matthew C. Hiemenz, Brennan Decker, Garrett Frampton, Lee A. Albacker, Jeffrey S. Ross

Summary: The study analyzed a large cohort of solid tumor cases to investigate CD274 copy-number changes and their correlation with PD-L1 protein expression. The prevalence of CD274 copy-number changes varied across different tumor types and was found to be significantly associated with PD-L1 positivity in certain tumor types, indicating its potential as a biomarker for immune checkpoint inhibitor therapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Multidisciplinary Sciences

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance

Changsheng Huang, Shengxiang Ren, Yaqi Chen, Anyi Liu, Qi Wu, Tao Jiang, Panjing Lv, Da Song, Fuqing Hu, Jingqing Lan, Li Sun, Xue Zheng, Xuelai Luo, Qian Chu, Keyi Jia, Yan Li, Jun Wang, Caicun Zou, Junbo Hu, Guihua Wang

Summary: This research discovered that PD-L1 K162 was methylated by SETD7 and demethylated by LSD2. Additionally, PD-L1 K162 methylation controlled the PD1/PD-L1 interaction and significantly enhanced the suppression of T cell activity in controlling cancer immune surveillance. The study demonstrated that PD-L1 hypermethylation was the key mechanism for anti-PD-L1 therapy resistance, identified PD-L1 K162 methylation as a negative predictive marker for anti-PD-1 treatment in patients with non-small cell lung cancer, and showed that the PD-L1 K162 methylation:PD-L1 ratio was a more accurate biomarker for predicting anti-PD-(L)1 therapy sensitivity.

SCIENCE ADVANCES (2023)

Add to Collection

Article Oncology

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

Robert Haddad, Tanguy Y. Seiwert, Laura Q. M. Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Andrew Albright, Robin Mogg, Mark Ayers, Lingkang Huang, Jared Lunceford, Razvan Cristescu, Jonathan Cheng, Ranee Mehra

Summary: This study found that tumor mutational burden (TMB), neoantigen load (NL), and T-cell-inflamed gene expression profile (Tcell(inf)GEP) were associated with response, and inflammatory biomarkers (Tcell(inf)GEP and PD-L1) showed a trend towards clinical response. The study also found concordance between HPV status detected by whole exome sequencing (WES) and p16 immunohistochemistry. These findings contribute to predicting response to anti-PD-1 therapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC

T. S. K. Mok, G. Lopes, B. C. Cho, D. M. Kowalski, K. Kasahara, Y. -l. Wu, G. de Castro Jr, H. Z. Turna, R. Cristescu, D. Aurora-Garg, A. Loboda, J. Lunceford, J. Kobie, M. Ayers, M. C. Pietanza, B. Piperdi, R. S. Herbst

Summary: This study evaluated the clinical utility of tissue tumor mutational burden (tTMB) and STK11, KEAP1, and KRAS mutations as biomarkers for pembrolizumab monotherapy versus platinum-based chemotherapy in PD-L1-positive advanced/metastatic non-small-cell lung cancer (NSCLC) patients. It suggests that tTMB could be a potential predictive biomarker for pembrolizumab monotherapy in NSCLC, and pembrolizumab is a standard first-line treatment regardless of STK11, KEAP1, or KRAS mutation status.

ANNALS OF ONCOLOGY (2023)

Add to Collection

Review Medicine, General & Internal

Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis

Wenjie Li, Yanjun Zhao, Hongjun Zhang, Wenying Zheng, Ruixuan Wang, Xing Gu

Summary: This study investigated the association between tumor mutational burden (TMB) and the therapeutic effect of Programmed Death 1/Programmed Death Ligand 1 inhibitors in non-small cell lung cancer. The results suggest that high TMB can serve as a potential predictive biomarker for improved progression-free survival and reduced overall response rate, but further investigation is needed to assess its predictive value in overall survival.

MEDICINE (2023)

Add to Collection

Article Immunology

Formin protein DIAPH1 positively regulates PD-L1 expression and predicts the therapeutic response to anti-PD-1/PD-L1 immunotherapy

Jie Mei, Yun Cai, Huiyu Wang, Rui Xu, Jiaofeng Zhou, Jiahui Lu, Xuejing Yang, Jiadong Pan, Chaoying Liu, Junying Xu, Yichao Zhu

Summary: This study aims to explore the expressions, prognostic values, and immunological correlations of Formins in cancer. DIAPH1 functioned as an oncogene in breast cancer and mediated epithelial-mesenchymal transformation (EMT) and PD-L1 expression. Moreover, DIAPH1 was overexpressed in most cancers and functioned as a novel pan-cancer immuno-marker, which could predict the response to anti-PD-1/PD-L1 immunotherapy.

CLINICAL IMMUNOLOGY (2023)

Add to Collection

Article Oncology

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Sen Yan, Han Zeng, Kaifeng Jin, Fei Shao, Zhaopei Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Jiejie Xu

Summary: The expression of NKG2A and PD-L1 together can be used as a combinatorial biomarker to predict the therapeutic response to immune checkpoint blockade in patients with muscle-invasive bladder cancer.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Pharmacology & Pharmacy

Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

A. Mennitto, E. Verzoni, F. Cognetti, R. Miceli, M. Milella, A. Mosca, V. E. Chiuri, A. Bearz, F. Morelli, C. Ortega, F. Atzori, M. Donini, M. Claps, V. Guadalupi, P. Sepe, V. Cappelletti, F. G. de Braud, G. Procopio

Summary: The RESORT trial demonstrated that sorafenib following radical metastasectomy in metastatic renal cell carcinoma did not prolong the relapse free survival (RFS). The updated 42-month follow-up data showed that surgery in selected patients should be considered to potentially improve survival, even though sorafenib did not improve RFS.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Prediction of Grade Reclassification of Prostate Cancer Patients on Active Surveillance through the Combination of a Three-miRNA Signature and Selected Clinical Variables

Paolo Gandellini, Chiara Maura Ciniselli, Tiziana Rancati, Cristina Marenghi, Valentina Doldi, Rihan El Bezawy, Mara Lecchi, Melanie Claps, Mario Catanzaro, Barbara Avuzzi, Elisa Campi, Maurizio Colecchia, Fabio Badenchini, Paolo Verderio, Riccardo Valdagni, Nadia Zaffaroni

Summary: The study investigated the potential of circulating microRNAs as specific markers associated with disease reclassification to improve patient selection based on standard clinicopathological features. A three-microRNA signature was identified to predict patient reclassification and enhance the performance of the clinical model including clinicopathological variables.

CANCERS (2021)

Add to Collection

Review Oncology

Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma

Pierangela Sepe, Arianna Ottini, Chiara Carlotta Pircher, Andrea Franza, Melanie Claps, Valentina Guadalupi, Elena Verzoni, Giuseppe Procopio

Summary: Non-clear cell renal cell carcinomas (ncRCC) are rare and lack standard treatments, with choices based on extrapolating results from clear cell RCC trials; the emergence of immunotherapy and new targeted drugs provides more diverse treatment options for the future.

CANCERS (2021)

Add to Collection

Article Oncology

Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)

Alessia Mennitto, Emma Zattarin, Massimo Di Maio, Davide Bimbatti, Ugo De Giorgi, Sebastiano Buti, Daniele Santini, Chiara Casadei, Mariella Soraru, Carlo Messina, Claudia Mucciarini, Giuseppe Di Lorenzo, Giandomenico Roviello, Consuelo Buttigliero, Marco Stellato, Pierangela Sepe, Melanie Claps, Valentina Guadalupi, Arianna Ottini, Sandro Pignata, Filippo G. De Braud, Elena Verzoni, Giuseppe Procopio

Summary: Cabozantinib showed improved postprogression survival in patients with metastatic renal cell carcinoma, suggesting it could be an effective treatment option after disease progression.

EXPERT REVIEW OF ANTICANCER THERAPY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Biomarker-driven immunotherapy for precision medicine in prostate cancer

Arianna Ottini, Pierangela Sepe, Teresa Beninato, Melanie Claps, Valentina Guadalupi, Elena Verzoni, Patrizia Giannatempo, Giulia Baciarello, Filippo de Braud, Giuseppe Procopio

Summary: Although immunotherapy has revolutionized cancer treatment, prostate cancer has not shown significant responses to immune checkpoint inhibitors. The current focus is on precision medicine to target treatments more accurately and identify responsive patients through predictive biomarkers.

PERSONALIZED MEDICINE (2022)

Add to Collection

Article Oncology

PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls

A. Franza, M. Claps, G. Procopio

Summary: PARP inhibitors have gained approval in metastatic castration-resistant prostate cancer (mCRPC) with mutations in homologous repair (HR)-related genes, but questions remain regarding drug resistance and PARPi-sensitivity in patients with alterations in various DNA damage response (DDR) related genes. This perspective article focuses on key issues related to PARP inhibitors in mCRPC, exploring potential combination therapeutic approaches and future directions in translational oncology research.

TRANSLATIONAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study)

Giuseppe Procopio, Pierangela Sepe, Melanie Claps, Sebastiano Buti, Maurizio Colecchia, Patrizia Giannatempo, Valentina Guadalupi, Luigi Mariani, Luca Lalli, Giovanni Fuca, Filippo de Braud, Elena Verzoni

Summary: This study demonstrates the promising efficacy of cabozantinib in untreated patients with mCDC.

JAMA ONCOLOGY (2022)

Add to Collection

Article Oncology

COVID-19 outbreak in Lombardy: Impact on reducing solid cancer diagnoses in 2020

Annalisa Trama, Alice Bernasconi, Laura Botta, Serena Di Cosimo, Rosalba Miceli, Melanie Claps, Fabio Badenchini, Roberto Lillini, Massimiliano Rubino, Paolo Lasalvia

Summary: The study aimed to analyze the year-long decline in cancer diagnoses in the Lombardy region of Italy on a population level, and characterize the tumors with the greatest reduction by patient age, sex, and tumor stage at diagnosis. Using healthcare utilization databases, the study compared the frequency of new cancer diagnoses in 2019 and 2020, observed two peaks in the decline, and found that diagnoses of common cancers remained below pre-pandemic levels. The study emphasized the importance of timely monitoring and interventions to prevent disruptions in diagnostic services for cancer patients during emergencies.

INTERNATIONAL JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial

Alessandra Raimondi, Giovanni Randon, Michele Prisciandaro, Filippo Pagani, Sara Lonardi, Carlotta Antoniotti, Silvia Bozzarelli, Andrea Sartore-Bianchi, Marco Tampellini, Laura Fanchini, Roberto Murialdo, Matteo Clavarezza, Alberto Zaniboni, Rosa Berenato, Margherita Ratti, Fausto Petrelli, Lorenzo Antonuzzo, Monica Giordano, Alessandro Rossi, Maria Di Bartolomeo, Massimo Di Maio, Filippo Pietrantonio, Federica Morano

Summary: In the study of RAS wild-type mCRC patients, age did not have a significant impact on survival outcomes when selecting maintenance strategies. However, younger patients showed a trend for increased chemotherapy-related adverse events, such as anemia, while experiencing significantly decreased EGFR-related hypomagnesemia and increased skin rash. Management of treatment-related adverse events should take into account the differential toxicity profile of age and sex.

INTERNATIONAL JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Laparoscopic retroperitoneal lymph-node dissection in metastatic nonseminomatous germ-cell tumors

Sebastiano Nazzani, Silvia Stagni, Davide Biasoni, Mario Catanzaro, Alberto Macchi, Antonio Tesone, Tullio Torelli, Ruggero Darisi, Vito Lo Russo, Claudia Colbacchini, Rodolfo Lanocita, Tommaso Cascella, Melanie Claps, Patrizia Giannatempo, Matteo Zimatore, Laura Cattaneo, Emanuele Montanari, Roberto Salvioni, Nicola Nicolai

Summary: This study retrospectively observed 151 patients undergoing L-PC-RPLND, and the results showed that L-PC-RPLND has a promising clinical application in the treatment of patients with residual tumors.

EJSO (2023)

Add to Collection

Review Oncology

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy

Achille Bottiglieri, Pierangela Sepe, Marco Stellato, Chiara Pircher, Giuseppe Fotia, Alberto Giovanni Leone, Valentina Guadalupi, Melanie Claps, Patrizia Giannatempo, Elena Verzoni, Giuseppe Procopio

Summary: Renal cell carcinoma (RCC) is commonly diagnosed at a localized or locally advanced stage, with surgery being the primary treatment option. However, there is a high relapse rate. Adjuvant agents like TKIs do not show clear efficacy in terms of DFS and have significant toxicity issues.

CANCER MANAGEMENT AND RESEARCH (2022)

Add to Collection

Article Oncology

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial

Filippo Pietrantonio, Paolo Manca, Sara Erika Bellomo, Simona Corso, Alessandra Raimondi, Enrico Berrino, Federica Morano, Cristina Migliore, Monica Niger, Lorenzo Castagnoli, Serenella Maria Pupa, Caterina Marchio, Maria Di Bartolomeo, Eleonora Restuccia, Chiara Lambertini, Josep Tabernero, Silvia Giordano

Summary: In the JACOB trial, the addition of pertuzumab to trastuzumab-chemotherapy did not significantly improve the survival of patients with metastatic HER2-positive gastric cancer. However, HER2 copy-number variation and AMNESIA panel may help in selecting patients who will benefit from HER2 inhibition. The analysis of HER2 CNV, HER2 expression, and AMNESIA showed correlations with overall response rate, progression-free survival, and overall survival.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Oncology

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

Giuseppe Procopio, Melanie Claps, Chiara Pircher, Luca Porcu, Pierangela Sepe, Valentina Guadalupi, Ugo De Giorgi, Davide Bimbatti, Franco Nole, Francesco Carrozza, Sebastiano Buti, Roberto Iacovelli, Chiara Ciccarese, Cristina Masini, Cinzia Baldessari, Laura Doni, Antonio Cusmai, Angela Gernone, Sarah Scagliarini, Sandro Pignata, Filippo de Braud, Elena Verzoni

Summary: The study demonstrates that cabozantinib as second-line therapy after immune-checkpoint inhibitors is effective in mRCC patients and can prolong survival. Additionally, the safety profile of the drug can be managed.

TUMORI JOURNAL (2023)

Add to Collection

Article Oncology

Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials

Alessandra Boccaccino, Daniele Rossini, Alessandra Raimondi, Martina Carullo, Sara Lonardi, Federica Morano, Daniele Santini, Gianluca Tomasello, Monica Niger, Alberto Zaniboni, Francesca Daniel, Sara Bustreo, Letizia Procaccio, Matteo Clavarezza, Samanta Cupini, Michela Libertini, Federica Palermo, Filippo Pietrantonio, Chiara Cremolini

Summary: In clinical trials, safety assessment has traditionally focused on the rate of high-grade and serious adverse events. However, a new approach that considers chronic low-grade adverse events, single patient's perspective, and time-related information should be considered for long-lasting treatments like maintenance strategies in metastatic colorectal cancer. The study found that most chemotherapy-related adverse events reach their highest level in the early cycles and then gradually decrease.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer

Lorenzo Castagnoli, Simona Corso, Alma Franceschini, Alessandra Raimondi, Sara Erika Bellomo, Matteo Dugo, Federica Morano, Michele Prisciandaro, Silvia Brich, Antonino Belfiore, Andrea Vingiani, Maria Di Bartolomeo, Giancarlo Pruneri, Elda Tagliabue, Silvia Giordano, Filippo Pietrantonio, Serenella M. Pupa

Summary: In this study, cotargeting HER2 and FASN was found to enhance the efficacy of anti-HER2 therapy, providing a new opportunity for treating trastuzumab-resistant HER2+ gastric cancer.

CELLULAR ONCOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.